Equities research analysts at Wedbush started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm set an "outperform" rating and a $22.00 price target on the stock. Wedbush's price target indicates a potential upside of 31.19% from the stock's current price.
Separately, William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.
Read Our Latest Stock Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
Shares of Telix Pharmaceuticals Limited American Depositary Shares stock traded down $0.59 during mid-day trading on Thursday, reaching $16.77. 12,873 shares of the stock traded hands, compared to its average volume of 26,048. The business has a 50-day moving average of $16.76 and a 200 day moving average of $16.83. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $13.61 and a fifty-two week high of $30.36.
Institutional Trading of Telix Pharmaceuticals Limited American Depositary Shares
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA purchased a new stake in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
